GlassScriptPhysician profile
Todd Jonathan Harris
NPI 1619004595
$567.33
in general payments reported to CMS, 2019-2025
20 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $169 · 2024: $265 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $567.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $75.00 | 2024 | Ingrezza |
| Abbvie INC. | $50.73 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.00 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $36.69 | 2025 | Airsupra, Breztri |
| Azurity Pharmaceuticals, INC. | $35.21 | 2023-2025 | Edarbyclor, Azmiro |
| Novartis Pharmaceuticals Corporation | $34.90 | 2024 | |
| Novo Nordisk INC | $33.70 | 2023-2025 | |
| Lilly USA, LLC | $31.62 | 2024 | Zepbound, Jardiance |
| Sun Pharmaceutical Industries INC. | $23.36 | 2025 | |
| Astellas Pharma US INC | $23.21 | 2023 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.93 | 2025 | Ofev |
| Pfizer INC. | $20.84 | 2024 | |
| Xeris Pharmaceuticals, INC. | $19.65 | 2023 | Gvoke Hypopen |
| Ironwood Pharmaceuticals, INC | $18.87 | 2023 | Linzess |
| Amgen INC. | $18.67 | 2023 | Evenity, Prolia |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $18.34 | 2023 | Nuedexta |
| Merck Sharp & Dohme LLC | $18.10 | 2023 | Verquvo |
| Glaxosmithkline, LLC. | $17.15 | 2024 | Trelegy Ellipta, Arexvy |
| Lundbeck LLC | $16.62 | 2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.74 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.